Search clinical trials for: Prevnar 13™

Total 4257 results

St. Antonius Hospital

Completed

Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status (CAPolista)

Pneumonia | Immune Response | Streptococcus Pneumoniae

Netherlands
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (PNEU-PED-EU-2)

Pneumococcal Infections

Denmark, Finland, Italy, Norway, Sweden
Murdoch Childrens Research Institute
National Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaborators

Completed

Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam

Pneumococcal Vaccines

Vietnam
Merck Sharp & Dohme LLC

Completed

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Pneumococcal Infections

United States, Brazil, Colombia, Dominican Republic, Greece, Italy, Panama
Merck Sharp & Dohme LLC

Completed

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) (PNEU-TRUE)

Pneumococcal Infections | Pneumonia, Pneumococcal

United States, Australia, Chile, Denmark, Finland, United Kingdom
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) (PNEU-WAY)

Pneumococcal Infections

United States, France, Peru, South Africa, Thailand
Merck Sharp & Dohme LLC
MCM Vaccines B.V.

Completed

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Virus Diseases | Bacterial Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

Pneumococcal Infections

United States, Australia, Canada, Chile, New Zealand, Poland, Russian Federation
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Pneumococcal Infections

United States, Australia, Canada, Finland, Germany, Israel, Malaysia, Peru, Taiwan, Thailand
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) (PNEU-WAY PED)

Pneumococcal Infections

South Africa, Thailand, Ukraine
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (PNEU-PED)

Pneumococcal Infections | Pneumococcal Vaccines

United States, Puerto Rico, Thailand, Turkey
MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Virus Diseases | Bacterial Infections
GlaxoSmithKline

Completed

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Haemophilus Influenzae Type b

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (PNEU-PATH)

Pneumococcal Infections

United States, Korea, Republic of, Spain, Taiwan
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (PNEU-PED-EU-1)

Pneumococcal Infections

Australia, Belgium, Czechia, Estonia, Germany, Greece, Poland, Russian Federation, Spain
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

Pneumococcal Infections

United States, Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Mexico, Sweden
Pfizer

Completed

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Infections, Meningococcal

Australia, Canada, Czechia, Panama, South Africa, Turkey
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

Pneumococcal Infections

Japan
GlaxoSmithKline

Completed

Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants

Infections, Streptococcal

Poland, Germany, Czechia, Spain
MCM Vaccines B.V.
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Virus Diseases | Bacterial Infections
London School of Hygiene and Tropical Medicine
University College, London; Bill and Melinda Gates Foundation; Wellcome Trust; KEMRI-Wellcome... and other collaborators

Active, not recruiting

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (FPCV)

Pneumococcal Infection | Streptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection Against

Kenya
GlaxoSmithKline

Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Neisseria Meningitidis | Haemophilus Influenzae Type b

Germany, France, Canada
Wuhan BravoVax Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention; Liaoning Chengda...

Recruiting

Phase I Clinical Trial of a Candidate PCV13 in Healthy People

Pneumococcal Infections

China
Papua New Guinea Institute of Medical Research
The University of Western Australia

Unknown

Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children (PCV1103)

Pneumonia | Sepsis | Meningitis | Otitis Media | Bacteraemia

Papua New Guinea
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

Pneumococcal Infections

United States, Canada, Denmark, Finland, Israel, Spain
GlaxoSmithKline

Completed

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b

Finland, Dominican Republic
University of Oxford

Completed

A Study of the Interaction Between BCG And MenC Immunisation: BAM (BAM)

Immune Response | BCG Infection | Reaction - Vaccine

United Kingdom
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) (PNEU-PLAN)

Pneumococcal Infections

Finland, Malaysia, Poland, Russian Federation, Thailand
Jiangsu Province Centers for Disease Control and...
Beijing Minhai Biotechnology Co., Ltd

Completed

A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Pneumonia

China
Michigan State University
Pfizer

Completed

Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

End Stage Renal Disease

United States
Merck Sharp & Dohme LLC

Completed

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Measles | Rubella | Mumps | Varicella
University Hospital Southampton NHS Foundation...
Solent NHS Trust

Unknown

Paediatric Post Pneumococcal Conjugate Vaccine Nasopharyngeal Carriage Study

Pneumococcal Conjugate Vaccine | S. Pneumoniae

United Kingdom
GlaxoSmithKline

Completed

Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™

Streptococcus Pneumoniae Vaccines | Infections, Streptococcal

Mexico
Lakehead University

Completed

The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13

Chronic Kidney Diseases

Canada
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)

Pneumococcal Infections

Japan
Pfizer

Completed

Prevenar13 Post Market Surveillance

Healthy

Korea, Republic of
University of British Columbia
Canadian Institutes of Health Research (CIHR); University of Calgary; Alberta... and other collaborators

Completed

CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study

Streptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection Against

Canada
Thomas Jefferson University
Acelity

Recruiting

Evaluation of Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications (PREVENA-AMP)

Amputation | Seroma | Wound Infection, Surgical | Wound Dehiscence | Lymph Leakage | Amputation; Postoperative, Sequelae

United States, Italy
CanSino Biologics Inc.
Henan Center for Disease Control and Prevention

Completed

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

Pneumococcal Infections | Bacterial Infections | Streptococcal Infections

China
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) (PNEU-AGE)

Pneumococcal Infections

Taiwan, United States, Canada, Japan, Spain
Nuron Biotech Inc.

Unknown

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

Infectious Disease

United States
Sanofi

Completed

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

Pertussis | Tetanus | Diphtheria | Polio | Haemophilus Infection

United States
Affinivax, Inc.

Completed

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Healthy Volunteers | Pneumococcal Disease

United States
Pfizer

Completed

Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos

Pneumococcal Disease

Philippines
GlaxoSmithKline
Affinivax, Inc.

Recruiting

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of AFX3772 Vaccine in Healthy Infants

Pneumococcal Infections | Pneumonia, Pneumococcal | Pneumonia, Bacterial

United States, Puerto Rico
Medical University of South Carolina

Completed

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

Aging | HIV Lipodystrophy

United States
AbbVie

Completed

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis (BALANCE-EXTEND)

Rheumatoid Arthritis

United States, Belgium, Bulgaria, Chile, Czechia, Hungary, Israel, Latvia, Mexico, New Zealand, Poland, Puerto Rico, Russian Federation, Slovakia, South Africa, Spain, Ukraine, United Kingdom

Search clinical trials for: Prevnar 13™

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations